Omeros, which is developing drugs for the treatment of surgery-related inflammation and pain, raised $68 million by offering 6.82 million shares at $10, at low end of the proposed $10 to $12 range. Shares are expected to begin trading Thursday on the NASDAQ under the symbol OMER. Deutsche Bank was lead manager on the deal.
